USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TOMEGAVAX, INC.
Address:
505 NW 185TH AVE
BEAVERTON, OR 97006-3448
Phone:
N/A
URL:
N/A
EIN:
145122209
DUNS:
968353347
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $524,506.00 2
SBIR Phase II $2,965,403.00 1
STTR Phase I $872,923.00 2

Award List:

Spread-deficient HCMV-vectored vaccines

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$299,835.00
Agency:
HHS
Principal Investigator:
Emily E. Marshall – 503-341-1697
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to establish human cytomegalovirus (HCMV) as a new human vaccine vector platform. In non-human primate models, CMV-vectored vaccines have shown unprecedented protection against immunodeficiency viruses and similar vaccines are… More

A Synthetic Human Cytomegalovirus Vaccine Platform

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$573,060.00
Agency:
HHS
Principal Investigator:
Sanjay Vashee – 301-795-7254
Research Institution:
OREGON HEALTH AND SCIENCE UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis… More

An effector memory T cell-based therapeutic cervical cancer vaccine

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$224,671.00
Agency:
HHS
Principal Investigator:
Eric Bruening – 503-341-1697
Abstract:
DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors carrying oncogenes of high risk human papillomaviruses (HPV) as novel therapeutic vaccines against cervical cancer. Although recently launched prophylactic vaccines protect against HPV… More

CMV Vectored Herpes Simplex Vaccine

Award Year / Program / Phase:
2014 / STTR / Phase I
Award Amount:
$299,863.00
Agency:
HHS
Principal Investigator:
Daniel N. Streblow – 503-494-2434
Research Institution:
OREGON HEALTH AND SCIENCE UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. HSV-2 is widely prevalent in the population causing recurrent… More

A human cytomegalovirus-based immunotherapy for HIV-1

Award Year / Program / Phase:
2014 / SBIR / Phase II
Award Amount:
$2,965,403.00
Agency:
HHS
Principal Investigator:
Eric Bruening – 503-341-1697
Abstract:
DESCRIPTION: The ultimate goal of this project is to develop an immunotherapy for human immunodeficiency virus (HIV)-1 based on a spread-deficient cytomegalovirus (CMV)-derived vaccine expressing tailored antigens designed for maximal coverage of clade Bepitopes. In non-human primate models,… More